At 9.7% CAGR, Insulin Delivery Devices Market Size to hit USD 33.05 Billion in 2028, Says Brandessence Market Research

LONDON, Jan. 3, 2022 /PRNewswire/ -- The Insulin Delivery Devices Market size is witness robust growth at a CAGR of 9.7% during the 2021-2028 period. The Insulin Delivery Devices Market size reached a valuation of USD 18.33 Billion in 2021, and is likely to grow to USD 33.05 Billion by 2028 end, Analysis by Brandessence Market Research.

Increasing geriatric population is the key factor driving the growth of Global Insulin Delivery Devices Market. Insulin is a necessary part of the treatment plan for all people with Type 1 diabetes and many with Type 2. Insulin helps get glucose from the bloodstream into the muscle and fat cells to be used for fuel. It cannot be taken as a pill or a swallowed liquid, because it would be broken down by the digestive system before it reached the bloodstream, where insulin does its work. Thus, insulin is injected or infused into the fatty tissue under the skin

Request a Sample Report: @ https://brandessenceresearch.com/requestSample/PostId/518 

According to the World Health Organization (WHO), number of diabetics rose to 422 million in 2014 rising from a meagre 108 million in 1980. Diabetes is known to be a deadly condition, with 1.5 million deaths globally in 2019. Apart from fatalities, the condition also results in blindness, amputations, kidney failure, stroke, and heart attacks, making it a deadly reality for millions around the world. The insulin delivery systems remain key to maintaining good health for millions of diabetics around the world, and promising application of these with effective delivery of exact dosage remains key drivers of growth in the insulin delivery devices market. The high-costs of insulin delivery devices remains the key constraint to growth.

Global Insulin Delivery Devices Market Segmentation:

By Type:

• Insulin Syringe
• Insulin Pens
• Tethered
• Patch
• Insulin Needles
• Insulin Inhalers
• External Insulin
• Disposable
• Reusable
• Insulin Jet Injectors
• Insulin Pumps
• Implantable Insulin

By Distribution Channels:

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacie

By End-User:

• Clinics
• Ambulatory Care Centre
• Hospital
• Homecare

The insulin delivery devices market is a fragmented, and competitive landscape. The landscape remains innovative, as products like automated insulin delivery devices promise a more precise and accurate dosage, along with increased delivery on time. These devices are likely to become very popular in old-age homes globally, as high number of diabetics, and burden of chronic care remain major concerns, and growing population of elderly remain major concerns around the world. The growing development of innovations promise new opportunities for gaining higher market share for key players in the insulin delivery devices market. Some key players in the insulin delivery devices market are:

• Novo Nordisk A/S (Denmark)
• Becton, Dickinson and Company
• Animas Corporation (U.S.)
• Ypsomed Holding AG (Switzerland),
• Tandem Diabetes Care.
• Medtronic plc
• Eli Lilly and Company
• Becton, Dickinson and Company
• Tandem Diabetes Care Inc.
• F. Hoffmann-La Roche Ltd.
• B. Braun Melsungen AG
• Insulet Corporation

Insulin Delivery Devices Market: Notable Developments

Tandem Diabetes announced in its December, 2021 press release that the company expects its customer base to triple by 2027 end, thanks to introduction of multiple new products. The company expects its customer base to reach 1 million new patients, in the next five years, with growing number of type 1 diabetes patients. Its CEO, Leigh Vosseller noted that the company expects booming growth from both, type 1, and type 2 diabetes.

AMF medical announced in November, 2021 that its Sigi Insulin management system has received the breakthrough device designation by the US Food and Drug Adminstration (FDA). The device delivery system is designed to deliver bolus insulin, and basal insulin by using both variable, and set rates. The technology also relies on Bluetooth-technology to confirm, respond, and activate commands, while using devices like smartphones, and iController 

Request for Methodology of this report: https://brandessenceresearch.com/requestMethodology/PostId/518

Many types of insulin delivery devices including Insulin syringes, external insulin pumps, implantable insulin pumps, insulin pumps, insulin injection aids, insulin jet injectors, insulin inhalers, among others remain key to diabetes management for millions globally. Devices like direct subcutaneous insulin injection remain the widely used form of delivery. This method relies on merely a needly and a syringe. Many patients also prefer using devices like external insulin pumps, due to their effective dosage systems with precise, and accurate amount of needed dosage. However, these remain highly expensive, and hard to access, limiting their reach to patients. Devices like insulin pen also remain a popular mechanism to deliver insulin dosage on-the-go, and their disposable nature makes them suitable for patients who are travelling. Insulin inhalers, insulin jet injectors, and insulin injection aids remain the most advanced technological aids to people with diabetes. The growing awareness of these devices, and suitability of many for insurance reimbursement make them a promising prospect for diabetes management in the near future.

Insulin Delivery Devices Market: Key Trends

• The insulin delivery devices market is divided on the basis of product into pens, pen needles, syringes, and others including jet injectors, inhalers, and transdermal patches. Among these, the insulin pen accounted for highest growth in 2018, and is likely to hold an important share of the total revenues. Among insulin pens, the reusable pens are likely to hold the largest share of revenues, promising a noteworthy sub-segment. Furthermore, the external pumps are also expected to witness notable growth, as availability of reimbursement mechanisms, and increasing prevalence type 1 diabetes, along with rising expenditure on competing products remain important driver of growth.
• Among end-users, the homecare, clinics, and hospitals are important segments. Among these, the homecare segment is expected to account for highest growth. In countries like the US, the expenditure by agencies like Medicare remain the highest sources for healthcare services, as healthcare service costs spiral out of control. According to Centre for Medicare & Medicaid Services (CMS), the US government spending reached 4.1 trillion in 2020, growing by 9.7% in 2020. The changes in government policies, providing more support for average citizen also signal a more promising era for players in the insulin delivery devices market. However, despite the colossus volume of spending by the US government, the high costs of insulin still remains a concern. For example, while costs of insulin delivery devices can range from USD30, 000 to 50,000, the average spending per capital by the US government is limited to USD 12,530 per person, while the total spending amounted to over 19% of the total GDP. This signals that the government has reached its limits, and without the involvement of the private sector in bringing down costs, it would find it difficult to cater to segments like homecare, which are increasingly being funded by the taxpayer.

Insulin Delivery Devices Market: Regional Analysis

The Insulin Delivery Devices Market is segmented into North America, Europe, Asia-Pacific, Latin America and Africa. The North America is expected to capture the largest share of global insulin delivery devices market owing to the increasing pervasiveness of diabetes and a well-developed healthcare sector. According to Canadian Statistics, in the year 2017, 7.3% of Canadians people aged between 12 and older (roughly 2.3 million people) reported being diagnosed with diabetes. Between 2016 and 2017, the percentage of males who reported being diagnosed with diabetes escalates from 7.6% in 2016 to 8.4% in 2017.The percentage of females remained consistent between the two years. On the other hand, the Middle East & Africa is expected to observe slow growth due to less exposure to healthcare services, lack of awareness, and stringent government rules and regulations.

Insulin delivery devices market report is divided into key regions North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Among these, the North America region is expected to register highest share of revenues during the forecast period. The high number of diabetics in the region, and increased efficacy of new products like automated insulin deliver systems, and growing investment from agencies like CMS in the healthcare sector remain key drivers of growth in the insulin delivery devices market. Asia Pacific also promises tremendous growth, as countries like China, India have invested in private reimbursement mechanisms, with increased liberal policies towards insurance companies.the growing public-private partnership in the healthcare sector promises more growth opportunities for technological advancements, which are expensive in nature, and require special means of funding like private insurance.

On Special Requirement Insulin Delivery Devices Market Report is also available for below region:

North America

• U.S, Canada

Europe

• Germany, France, U.K., Italy, Spain, Sweden, Netherland, Turkey, Switzerland, Belgium, Rest of Europe

Asia-Pacific

• South Korea, Japan, China, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest Of APAC

Latin America

• Mexico, Colombia, Brazil, Argentina, Peru, Rest of Latin America

Middle East and Africa

• Saudi Arabia, UAE, Egypt, South Africa, Rest Of MEA

Get Full Research Report: https://brandessenceresearch.com/healthcare/insulin-delivery-devices-market

Related Reports:

• Microalgae Market is Expected to Reach 4996.8 Million by 2027
• Warehouse Robotics Market to hit USD 10912.5 Million by 2027
• Electric Motors Market Size to hit 193.64 billion by 2027
• Virtual Reality in Gaming Market Expected to Reach USD 40993.1 Million, Globally by 2027
• Biophotonics Market to hit USD 109.23 Bn by 2027
• Skincare Market Size is Projected to Reach USD 198.13 Bn by 2027
• Industrial Hemp Market Accounted for USD 3.91 Bn in 2020 says Brandessence Market Research
• Anti-aging Market Size to hit USD 60.95 Billion in 2027
• MICE Industry is Expected to Reach USD 2307.4 Million by 2027

i-Factor: Live Market intelligence platform

I-Factor is our guaranteed seal to keep our clients ahead of the competition, always. This knowledge platform delivers real-time updates on key economic indicators, competitive landscape, changing demand, trends, customized regional insights, and more. The platform visualizes key data points to help make decision making agile, trustworthy, and holistic.  Register for free trail here @ https://brandessenceresearch.com/i-factor/login/userRegister

Brandessence Market Research & Consulting Pvt ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Website: https://brandessenceresearch.com 
Blog: Top 10 Metaverse Companies 

Mr. Vishal Sawant
Email: [email protected]
Email: [email protected]  
Corporate Sales: +44-2038074155
Asia Office: +917447409162

SOURCE Brandessence Market Research And Consulting Private Limited